logo
welcome
Reuters

Reuters

Eli Lilly forecasts weaker Q4 sales of weight-loss drug, Mounjaro than expected

Reuters
Summary
Nutrition label

78% Informative

Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter .

Lilly said it expects 2025 sales between $58 billion and $61 billion .

Analysts were expecting revenue of $58.52 billion .

VR Score

89

Informative language

98

Neutral language

23

Article tone

formal

Language

English

Language complexity

49

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links